Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Neumora Therapeutics, Inc.: Amended and restated bylaws effective upon closing of IPO, including provisions for advance notice, written consent prohibition, director removal, classified board, and forum selection (effective 2023-09-19).
- Change
- bylaw amendment
- Effective
- 2023-09-19
Exact text from the filing
On September 19, 2023, Neumora Therapeutics, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on September 19, 2023, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Neumora Therapeutics, Inc.: Amended and restated certificate of incorporation effective upon closing of IPO, including changes to authorized shares, preferred stock, director election, stockholder action, and forum selection provisions (effective 2023-09-19).
- Change
- charter amendment
- Effective
- 2023-09-19
Exact text from the filing
On September 19, 2023, Neumora Therapeutics, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on September 19, 2023, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.
View on SEC.gov